Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice

Neuroreport. 2010 Sep 15;21(13):897-901. doi: 10.1097/WNR.0b013e32833dbd2d.

Abstract

Complete deficiency of a member of the type II transmembrane serine protease family, tmprss1 (also known as hepsin), is associated with severe to profound hearing loss in mice and a gross enlargement of the tectorial membrane in the cochlea. Levels of thyroxine in these mice have been shown to be significantly lower when compared with wild-type controls. As thyroxine is critical for inner ear development, we delivered thyroxine to these mice during the prenatal or postnatal stage of development. Both the treatments could not ameliorate hearing loss or correct deformities in the tectorial membrane of these mutant mice, suggesting that a deficiency in tmprss1 affects thyroxine responsiveness in the inner ear in vivo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ear Diseases / congenital
  • Ear Diseases / drug therapy*
  • Ear Diseases / pathology
  • Ear, Inner / abnormalities*
  • Ear, Inner / pathology
  • Hearing / physiology
  • Hearing Tests
  • Mice
  • Mice, Knockout
  • Mutation / physiology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Serine Endopeptidases / genetics*
  • Serine Endopeptidases / physiology
  • Thyroxine / therapeutic use*

Substances

  • Serine Endopeptidases
  • hepsin
  • Thyroxine